

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Susan S. Rucker, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone 301/496-7056 ext. 245; fax 301/402-0220; e-mail ruckers@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Hybrid Adeno-Retroviral Vector for the Transformation of Cells

C Zheng, B O'Connell, BJ Baum (NIDCR) Serial No. 60/265,198 filed Jan 30, 2001

This invention described and claimed in this patent application provides for novel hybrid vectors which may be used for cell transformation either *in vivo*, *in vitro*, or *ex vivo*. The hybrid vectors, which are capable of integrating into the chromosome of the host cell and are capable of transforming dividing or non-dividing cells, have an adenoviral backbone and only a single retroviral long terminal repeat (LTR). Due to their hybrid nature, these vectors provide a means of efficient, reliable, long-term gene expression. Furthermore, unlike other chimeric or hybrid vector systems only a single vector is required to deliver a transgene of interest and retroviral structural proteins are not required. The vectors may be packaged and delivered via a viral particle or directly to the target cell.

ARG, a Human Gene Related to but Distinct From ABL Proto-Oncogene

GD Kruh, SA Aaronson (NCI) Serial No. 07/559,029 filed Jul 30, 1990 now US Patent 5,693,778 issued Dec 02, 1997

This patent relates to the identification, isolation and cloning of the gene ARG (abelson related gene) also known as ABL2. ARG/ABL2 is located on the long arm of chromosome 1 at 1q24-q25. It is a non-receptor tyrosine kinase. Recent work, by Iijima, et al. Blood 95(6): 2126-2131 (March 15, 2000) and Cazzaniga, et al Blood 94(12):4370-4373 (December 15, 1999), has demonstrated that ABL2/ARG is a partner with the ETV6/TEL gene. ETV6/TEL, located on the short arm of chromosome 12 at 12p13 has previously been implicated in hematological disease, particularly leukemias, through chromosomal translocations. The fusion protein derived from this partnership between ETV6/TEL and ARG/ABL2 includes exons 1-5 of ETV6 (5' PNT region) and the 3' portion of ARG/ABL2 beginning with exon 1B or 2 which contains all of the functional domains of ARG/ABL2. This new work suggests that ARG plays a role in AML and possibly other leukemias.

This work has been published at Kruh GD, et al. Science 234(4783):1545-8 (Dec 19, 1986) and Kruh GD, et al. PNAS, USA 87:5802 (Aug 1990).

Dated: March 6, 2001.

Jack Spiegel,

Director, Division of Technology, Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 01-6272 Filed 3-13-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National

Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Novel Attenuated Strains of Mycobacterium Tuberculosis

CE Barry, Y Yuan, D Crane (NIAID) DHHS Reference No. E-238-97/2 filed Jun 27, 2000

Licensing Contact: Carol Salata; 301/496-7735 ext. 232; e-mail: salatac@od.nih.gov

This invention provides for novel attenuated strains of *Mycobacterium tuberculosis* and *M. bovis*. Attenuation is achieved by deleting the gene encoding the alpha-crystallin heat shock protein ("acr gene"). This gene contributes to the virulence of the organism. Since this strain is isogenic with virulent *M. tuberculosis* but for this deletion, the full complement of antigens remains present and the organism is viable *in vitro*. The invention provides for vaccines and methods of vaccinating mammals for protection against *Mycobacterium sp.* that cause tuberculosis. This invention was filed as PCT/US98/14227 on Jul 09, 1998.

Methods and Compositions for Transforming Dendritic Cells and Activating T Cells

Patrick Hwu, Mark E. Reeves, Steven A. Rosenberg (NCI)

DHHS Reference Nos. E-040-96/0 filed Feb. 08, 1996, E-040-96/1 filed Feb. 07, 1997

(PCT/US97/02063); E-040-96/2 filed Jan. 07, 1999

Licensing Contact: Elaine White; 301/496-7056 ext. 282; e-mail: gesee@od.nih.gov

This invention describes a novel method for making transformed dendritic cells, which are potent antigen presenting cells capable of stimulating the immune system. Hematopoietic stem cells are transformed with a specific nucleic acid; the transformed cell is then differentiated into a dendritic cell *in vitro*. The nucleic acid produces a polypeptide, fragments of which are expressed on the major histocompatibility complex (MHC) receptors on the surface of the dendritic cell. These cells may then be used to activate T cells against specific target antigens. Use of specific antigens for transduction into the dendritic cells is described. The invention therefore may represent a valuable tool for use in the treatment of a number of diseases,

including various cancers and viral infections such as HIV.

Dated: March 6, 2001.

Jack Spiegel,

Director, Division of Technology, Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 01-6273 Filed 3-13-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, T32 Grant Application.

Date: March 12, 2001.

Time: 2 pm to 3 pm.

Agenda: To review and evaluate grant applications.

Place: 6116 Executive Boulevard., 8th Floor, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: David E. Maslow, Ph.D., Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard—Room 8117, Bethesda, MD 20892-7405, 301/496-2330.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 5, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-6255 Filed 3-13-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of meetings of the National Advisory Research Resources Council.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Research Resources Council, Executive Subcommittee.

Date: May 17, 2001.

Time: 8 am to 9 am.

Agenda: To discuss policy issues.

Place: National Center for Research Resources, National Institutes of Health, Conference Room 3B13, Building 31, Bethesda, MD 20892.

Contact Person: Louise E. Ramm, Ph.D., Deputy Director, National Center for Research Resources, National Institutes of Health, Building 31, Room 3B11, Bethesda, MD 20892, 301-496-6023.

Name of Committee: National Advisory Research Resources Council.

Date: May 17, 2001.

Time: 9:15 am to 3 pm.

Agenda: Report of Center Director and other issues.

Place: National Institutes of Health, 9000 Rockville Pike, Conference Room 10, Building 31C, Bethesda, MD 20892.

Closed: 3 pm to adjournment.

Agenda: To review and evaluate grant applications.

National Institutes of Health, 9000 Rockville Pike, Conference Room 10, Building 31C, Bethesda, MD 20892.

Contact Person: Louise E. Ramm, Ph.D., Deputy Director, National Center for Research Resources, National Institutes of Health, Building 31, Room 3B11, Bethesda, MD 20892, 301-496-6023.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333; 93.371, Biomedical Technology; 93.389, Research Infrastructure, National Institutes of Health, HHS)

Dated: March 6, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-6266 Filed 3-13-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, Review of Conference Grants (R13s).

Date: April 6, 2001.

Time: 2 pm to 3 pm.

Agenda: To review and evaluate grant applications.

Place: NIEHS—East Campus, Building 4401, Conference Room 122, 79 Alexander Drive, Research Triangle Park, NC 27709, (Telephone Conference Call).

Contact Person: J. Patrick Mastin, Ph.D., Scientific Review Administrator, National Institute of Environmental Health Science, P.O. Box 12233, MD EC-24, Research Triangle Park, NC 27709, 919-541-1446.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, Products/Devices/Biomarkers for Measuring Exposure to Environmental Agents: SBIR Initiative (RFA 00-009).